These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Utility of F-18 FDG PET/CT in screening for paraneoplastic neurological syndromes.
    Author: Matsuhisa A, Toriihara A, Kubota K, Makino T, Mizusawa H, Shibuya H.
    Journal: Clin Nucl Med; 2012 Jan; 37(1):39-43. PubMed ID: 22157026.
    Abstract:
    PURPOSE: The aim of this study was to assess the utility of positron emission tomography/computed tomography (PET/CT) for the investigation of patients with suspected paraneoplastic neurologic syndrome (PNS). MATERIALS AND METHODS: We reviewed the whole-body fluorodeoxyglucose (FDG) PET/CT studies (ordered by the neurology department) performed at our hospital between December 2005 and November 2010; 27 cases (16 men, 11 women; mean age, 65 years) who were suspected of having PNS were selected. RESULTS: Of the 27 patients, 6 (22%) had an abnormal FDG uptake. Of these 6 patients, 5 (19%) were histologically confirmed as having a malignancy. Of the 27 patients, 7 were tested for the presence of well-characterized paraneoplastic antibodies (anti-Hu, anti-Ri, anti-Yo); 1 had anti-Hu, but the patient did not have an abnormal FDG uptake or malignancy. CONCLUSIONS: PET/CT may be a useful screening tool for patients with clinically suspected PNS who do not exhibit well-characterized paraneoplastic antibodies. Therefore, we recommended that PET/CT should be performed for patients with clinically suspicious PNS regardless of the presence of well-characterized paraneoplastic antibodies.
    [Abstract] [Full Text] [Related] [New Search]